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FDG-PET for Evaluating the Antitumor
Effect of Intraarterial 3-Bromopyruvate
Administration in a Rabbit VX2 Liver
Tumor Model
Objective: We wanted to investigate the feasibility of using FDG-PET for evalu-
ating the antitumor effect of intraarterial administration of a hexokinase II inhibitor,
3-bromopyruvate (3-BrPA), in a rabbit VX2 liver tumor model.
Materials and Methods: VX2 carcinoma was grown in the livers of ten rabbits.
Two weeks later, liver CT was performed to confirm appropriate tumor growth for
the experiment. After tumor volume-matched grouping of the rabbits, tran-
scatheter intraarterial administration of 3-BrPA was performed (1 mM and 5 mM
in five animals each, respectively). FDG-PET scan was performed the day
before, immediately after and a week after 3-BrPA administration. FDG uptake
was semiquantified by measuring the standardized uptake value (SUV). A week
after treatment, the experimental animals were sacrificed and the necrosis rates
of the tumors were calculated based on the histopathology.
Results: The SUV of the VX2 tumors before treatment (3.87 1.51 [mean
SD]) was significantly higher than that of nontumorous liver parenchyma (1.72
0.34) (p < 0.0001, Mann-Whitney U test). The SUV was significantly decreased
immediately after 3-BrPA administration (2.05 1.21) (p = 0.002, Wilcoxon
signed rank test). On the one-week follow up PET scan, the FDG uptake
remained significantly lower (SUV 1.41 0.73) than that before treatment (p =
0.002), although three out of ten animals showed a slightly increasing tendency
for the FDG uptake. The tumor necrosis rate ranged from 50.00% to 99.90%
(85.48% 15.87). There was no significant correlation between the SUV or the
SUV decrease rate and the tumor necrosis rate in that range.
Conclusion: Even though FDG-PET cannot exactly reflect the tumor necrosis
rate, FDG-PET is a useful modality for the early assessment of the antitumor
effect of intraarterial administration of 3-BrPA in VX2 liver tumor.
epatocellular carcinoma (HCC) is one of the most common, lethal
malignancies throughout the world. The prognosis for patients with HCC
is generally poor, with fewer than 10% of patients surviving five years
after diagnosis, and the median survival period is 4 6 months for patients with
unresectable tumors (1 3). Since very few of these patients (10 15%) are candidates
for the surgery, transcatheter arterial chemoembolization (TACE) has been widely
used for treating hepatic tumors, especially when the tumors are not surgically
resectable (4, 5). However, the therapeutic efficacy of TACE in HCC is still limited
and the overall results of treatment remain unsatisfactory (6). Therefore, a new
strategy for the treatment of HCC is needed.
Highly malignant tumors exhibit the capacity to metabolize glucose to lactate at
much higher rates than normal cells, and this high glucose metabolic rate is determined
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Hby the hexokinase levels (7). Hexokinase catalyzes the first
step in the glycolytic pathway by converting glucose to
glucose 6-phosphate, which serves as fuel for the glycolytic
pathway for the production of adeuosine triphosphate
(ATP) and as a precursor for many biosynthetic processes
that are essential for rapid tumor growth (8 10). Rapidly
growing hepatomas are known to exhibit a high glucose
catabolic rate (11). Type II hexokinase isoenzyme is a form
of hexokinase that binds to the outer mitochondrial
membrane, and it is predominantly overexpressed in
hepatomas (12 15). Recent studies have demonstrated
that 3-bromopyruvate (3-BrPA) inhibits tumor glycolysis
by directly acting at the hexokinase level (16), and direct
intraarterial delivery of 3-BrPA was shown to be a safe
and effective strategy for treating VX2 tumor in a rabbit
liver tumor model (17). 
Positron emission tomography (PET) is a molecular
imaging technique that provides images of physiologic
processes. 18F-2-fluoro-2-deoxy-D-glucose (FDG) is a
radiopharmaceutical analogue of glucose, and it is metabo-
lized in a similar fashion to glucose in that FDG is
transported across cell membranes by glucose transporter
proteins and it is then phosphorylated (18). The rate of
FDG uptake by the tumor cells is proportional to their
metabolic activity. FDG is phosphorylated like glucose to
form FDG-6-phosphate, but unlike glucose, it is not further
metabolized and instead becomes trapped in metabolically
active cells (19, 20). Because of the similarity of FDG to
glucose, glucose metabolic rates can be quantified with
PET imaging and so they can be applied for evaluating
tumors with a high glucose catabolic rate. 
There has been a recent report on the antitumor effect of
3-BrPA via intraarterial administration in rabbit VX2 liver
tumor (17), but the analysis was done by pathology only
and not with FDG-PET. Another report proved the
feasibility of employing FDG-PET to evaluate the antitu-
mor effect of 3-BrPA via intraperitoneal or direct infusion
in rabbit AS-30D tumor (21). However, to the best of our
knowledge, reports on the role of FDG-PET for evaluating
the antitumor effect of intraarterial administration of 3-
BrPA have not yet been published. Therefore, the purpose
of our study was to investigate the feasibility of using FDG
PET for evaluating the antitumor effect of a hexokinase II
inhibitor, 3-BrPA, in experimentally induced liver tumor
via intraarterial drug administration.
MATERIALS AND METHODS
VX2 Liver Tumor Model  
The study was approved by the animal care committee
of Seoul National University Hospital. The rationale for
selecting VX2 liver tumor as the experimental model is as
follows: its blood supply is similar to that of human
hepatoma, it grows rapidly and becomes a sizable tumor
that’s easily identified by imaging, and it has a high glycol-
ysis rate and elevated levels of mitochondrial bound
hexokinase, which are characteristics of advanced stage
tumors (8). In addition, catheter manipulation in a rabbit is
relatively easy in the hepatic artery from the common
femoral artery for delivering pharmacological agents (8,
11). Thirteen adult New Zealand white rabbits weighing
2.5 3.0 kg each were used. The VX2 carcinoma strain had
been maintained by means of successive transplantation
into the hind limbs of carrier rabbits. Anesthesia was
induced with intravenous ketamine hydrochloride (50 mg
per kilogram of body weight; Ketamine, Yuhan, Korea)
and 2% xylazine (0.1 ml/kg; Rompun, Bayer, Germany).
0.1 ml of minced VX2 carcinoma was implanted through a
midline subxyphoid incision into the subcapsular
parenchyma of the left medial lobe of the liver. This
method allows the growth of a single solitary, well-
demarcated tumor in the liver of each recipient rabbit (11).
The animals were used for experiments two weeks after
the tumor implantation, when the tumors were expected to
be a round shape 15 30 mm in diameter.
CT Evaluation of the Tumor Volume and the
Enhancement Pattern  
One day before intraarterial administration of 3-BrPA,
spiral CT was performed (MX 8000; Philips Medical
Systems, Best, The Netherlands) with the animals in the
supine position. Nonenhanced CT was performed to cover
the entire liver (3 mm collimation, 1.5 pitch and a 1 mm
reconstruction interval). For contrast enhanced CT, 13 ml
of contrast material (Iopromide, Ultravist; Schering, Berlin,
Germany) was injected at a rate of 0.5 ml/sec through the
auricular vein by an autoinjector (CT 9000 ADV Digital
Injection System, Liebel-Flarsheim, Cincinnati, OH). With
using a bolus tracking technique, a hepatic arterial and
portal venous phase image was obtained at 16-second
intervals. 
On the CT scan, the location and the size of the tumor
was measured by two radiologists working in consensus.
The volume (V) of the tumor was calculated by the
equation V = L x S
2/2, where L and S are the the shortest
and longest diameters, respectively, of the tumor (22). On
the basis of calculated tumor volume, the animals were
divided into two groups, i.e. the low dose and high dose 3-
BrPA groups, to induce various degrees of tumor necrosis.
Animals with similar sized tumors were evenly distributed
to each group to minimize any possible bias. A total of ten
rabbits were treated with intraarterial administration of 3-
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scans or during the procedures: a low dose was 1 mM of 3-
BrPA (n = 5), and a high dose was 5 mM of 3-BrPA (n =
5). The dose of 3-BrPA was determined according to the
results of experiments performed by Ko et al., where
complete inhibition of glycolytic activity of the VX2 tumor
was induced with 5 mM of 3-BrPA (16). No control group
was included in this experiment. Along with the volume
measurements, the enhancement pattern of each tumor, as
compared with the background liver, was also evaluated
on the hepatic arterial and portal venous phases. Follow up
CT scan was done one week later after 3-BrPA administra-
tion. 
Intraarterial Administration of 3-BrPA
The concentrations of 3-BrPA (Aldrich Chemical Co.,
Cat. No. 238341) in the 1 mM and 5 mM administrations
were prepared with sterile PBS (phosphate-buffered
saline). The solution was sterilized with using a Sartorius’
Minisart 0.2 um filter unit. Freshly made solutions were
used in all of the studies.
Two weeks after the implantation of VX2 tumor in liver,
fluoroscopy-guided intraarterial injection of 3-BrPA was
performed at an angiography suite. Under the general
anesthesia, surgical arteriotomy was done to expose the
right common femoral artery, into which a 5-Fr dilator was
placed as a substitute for an arterial sheath. Celiac arteriog-
raphy was performed using a 2-Fr microcatheter (Progreat
Microcatheter, Terumo, Japan), to identify the hepatic
arterial anatomy and the feeding artery of the tumors. The
left hepatic artery was selectively catheterized via the
common hepatic artery. After the catheter was advanced
to an appropriate position in the left hepatic artery, freshly
made 3-BrPA solution (1 mM and 5 mM, 25 ml each) was
infused directly into the targeted artery for two minutes.
The catheter was then removed and the femoral artery was
ligated. The animals were monitored after the procedure
and they were given analgesics (intramuscular injections of
1 2 mg of meloxicam; Mobic ; Boehringer Ingelheim,
Germany) when they showed signs of physical distress.
FDG-PET Protocol
FDG-PET scanning was done with a scanner (ECAT
EXACT 47; Siemens CTI, Knoxville, TN) that had an
intrinsic axial resolution of 6.2 mm and it could image 47
contiguous, 3.4-mm-thick planes simultaneously for a
longitudinal field of view of 16.2 cm. All the rabbits fasted
at least 24 hours prior to the study, and their bladders
were emptied by insertion of 5 Fr Foley catheter. The
entire procedure was done under general anesthesia.
Before the administration of FDG, transmission scanning of
the whole body was performed by using a 68Ge
(Germanium-68) rod source for attenuation correction.
Emission scans were obtained 45 minutes after the
injection of 37 mBq of FDG. Image reconstruction was
performed with an iterative reconstruction ordered-subset
expectation maximization (OSEM)-based algorithm that
included 16 subsets and six iterations. OSEM was
performed with a Gaussian filter. Regions of interests
(ROIs) were placed in the center of the tumor (crystal size:
4 4 20 mm, pixel size: 2.57 2.57 3.37 mm). PET
images (transverse, coronal and sagittal) were
reconstructed by using segmented attenuation correction
and the images were corrected for decay. Scanning was
performed three times for the experiment; the day before,
immediately after and a week after the administration of 3-
BrPA. PET scanning before and after treatment followed
the CT scanning on the same day.
FDG-PET Data Analysis
Liver CT scans were used to localize the tumor before
PET was performed. Two qualified physicians who were
experienced in nuclear medicine and who were unaware of
pathologic results, but they were aware of the CT findings,
interpreted the PET scans. The images were reviewed in
the transverse, coronal, and sagittal planes by using an
interactive video display system (SPARC station 10; Sun
Microsystems, Mountain View, CA). Interpretation
included the semiquantification of the FDG uptake by
using the peak standardized uptake value (SUV) on the
emission images obtained 45 minutes after injection of
FDG. After visually finding an area of the highest FDG
uptake, the physician outlined a region of interest on the
area of the highest uptake. An SUV normalized for the
injected dose and body weight was obtained for each pixel
by using a following method; SUV = ROI activity/(injected
dose/body weight), where the ROI activity was measured
in millicuries per milliliter, the injected dose was measured
in millicuries and the body weight was measured in grams.
The maximum pixel value of the ROI was chosen as the
peak SUV. The SUV decrease rate of each tumor was
obtained by using the following formula; the SUV decrease
rate = (1-SUV of post-treatment/SUV of pre-treatment)
100, and this was calculated immediately after and a week
after treatment. The SUV of the initial treatment, the SUVs
immediately after and at a week after treatment and SUV
decrease rate immediately after and at a week after
treatment were correlated with the tumor necrosis rate
(Spearman rank correlation test). 
Evaluation of the Antitumor Effect
Follow up CT was performed at one week after the
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pattern on each phase was observed. The animals were
sacrificed for histologic investigation with an overdose of
pentobarbital sodium (Pentothal; Choong Wae Pharmacy,
Seoul, Korea). Tumor volumes after the treatment were
measured on the cut surface of the specimens and these
were compared with those observed on CT before
treatment. The antitumor effects were evaluated with using
microscopic methods. The whole livers of the rabbits were
explanted and fixed in 10% buffered formaldehyde
solution. The part of the liver that contained the tumor was
sliced at 5 mm-intervals in the axial plane that
corresponded to the plane of the CT scan, and the sections
were completely embedded in paraffin for histologic
examination, after which the 4  m-thick sections were
stained with hematoxylin and eosin. Histologic changes
and the extent of residual viable tumor was assessed via
visual inspection by an experienced pathologist. To
quantify the antitumor effects, the proportion of the viable
tumor versus that of the entire tumor was estimated. The
overall proportion of viable tumor was calculated on the
basis of the average of the percentage in each slice. The
tumor necrosis rate was defined as 100-viable tumor
proportion (%).
Statistical Analysis
Differences between subgroups were examined by using
the Mann Whitney U test and the Wilcoxon signed rank
test. Univariate correlations were examined by using
Spearman’s rank correlation test. A p value of less than
0.05 was considered as a statistically significant difference.
Statistical data analyses were performed with MedCalc for
Windows (MedCalc Software, Mariakerke, Belgium).
RESULTS
CT Findings and Correlation with the Tumor Necrosis
Rate
Chronological changes of the tumor volumes and
enhancement pattern on CT, as well as the SUV in each
animal, are described in Table 1. The CT observed
volumes of the tumors before treatment ranged from
862.41 to 4,851.00 mm
3 (2,094.59 1,305.50 [mean
SD]) and those tumor volumes after treatment on the
pathologic specimens ranged from 451.25 to 2,916.00 mm
3
(1,395.75 mm
3 839.96), and the volume decrease rate
ranged from 0 to 56.32% (31.57% 20.11). Comparison
of the change of tumor volumes on CT was not possible
because the boundary of each tumor on CT was masked
with the peritumoral ischemic changes caused by the drug
infusion (Fig. 1). The tumor volumes were significantly
decreased after treatment in all animals (p = 0.008,
Wilcoxon signed rank test), but the volume decrease rate
showed no correlation with the tumor necrosis rate
(Spearman r =  0.32, p = 0.37)
Before treatment, eight out of ten tumors showed
peripheral or septum-like enhancement on the hepatic
arterial phase and washout on the portal venous phase,
which is characteristic of hypervascular tumors (Fig. 1). On
the one week follow up CT scans, all of these enhanced
portions on the arterial phase had decreased or
disappeared. 
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Table 1. Chronological Changes of VX2 Liver Tumor after 3-BrPA Administration
Tumor Volume CT Enhancement Pattern
Tumor  (mm
3) (HAP/PVP)
SUV 
Necrosis  No. Group
Initial 1  week 
Rate (%) (on CT) (on specimen)
Initial 1 week Initial Immediate 1 week
1 4,851.00 2,268.00 high/low* high/low 3.84 1.47 (61.72  )  2.10 (45.31) 80.00
2 low dose 2,745.50 1,575.00 high/low low/low 4.69 1.42 (69.72) 2.70 (42.43) 80.00
3 3-BrPA  1,143.45 1,009.79 low/low low/low 6.50 5.07 (22.00) 1.51 (76.77) 50.00
4 (1 mM) 0,862.41 0,451.25 high/low low/low 3.00 1.35 (55.00) 0.50 (83.33) 85.00
5 1,436.50 0,907.50 low/low low/low 2.49 1.40 (43.78) 1.00 (59.84) 70.00
6 3,240.00 2,916.00 high/low low/low 3.26 0.99 (69.63) 1.00 (69.33) 96.00
7 high dose  2,123.58 1,267.47 high/low low/low 3.42 2.00 (41.52) 1.95 (42.98) 99.00
8 3-BrPA  2,708.57 2,250.00 high/low low/low 6.33 2.91 (54.03) 0.41 (93.52) 99.90
9 (5 mM) 0,927.34 0,405.00 high/low low/low 2.85 2.47 (13.33) 1.70 (40.35) 95.00
10 0,907.50 0,907.50 high/low low/low 2.27 1.45 (36.12) 1.20 (47.14) 99.90
Nate.  HAP = hepatic arterial phase, PVP = portal venous phase, SUV = standardized uptake value, * high (or low) = when density of the tumor is higher 
(or lower) than that of background liver parenchyma.    Rates of SUV decrease after treatment are given in the parentheses of each column of SUV.FDG-PET Findings
The SUV of the initial tumors in all rabbits ranged from
2.27 to 6.50 (3.87 1.51 [mean SD]), and those of the
nontumorous liver parenchyma ranged from 1.34 to 2.61
(1.72 0.34). The FDG uptake of the VX2 tumor was
significantly higher than that of the nontumorous liver
parenchyma (p < 0.0001, Mann-Whitney U test). 
The SUV was significantly decreased immediately after
3-BrPA administration (before treatment: 3.87 1.51
[mean SD], immediately after treatment: 2.05 1.21, p =
0.002, Wilcoxon signed rank test). On the one week follow
up PET scan, the FDG uptake remained significantly lower
than that before treatment (1.41 0.73, p = 0.002), and
the SUV was persistently decreased in seven rabbits, but it
showed a slightly increasing tendency in three rabbits
(animals 1, 2 and 6) (Fig. 2). The decrease rate of SUV in
each tumor after 3-BrPA administration ranged from 13.33
to 69.72 immediately after treatment and from 40.35 to
93.52 a week after treatment (Table 1).
Tumor Necrosis Rate
Under microscopic examination, the tumors after 3-
Park et al.
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Fig. 1. A. Axial CT scan before treatment, the hepatic arterial phase (left) and the portal venous phase (right). Tumor is well demarcated
in the left lobe of the liver. It shows irregular peripheral and septal enhancement and central low attenuation in the arterial phase (left,
arrow). On the portal venous phase, arterial enhancement of the tumor washed out (right, arrow). 
B. Celiac arteriography shows hypervascular tumor staining in the left lobe of the liver (arrow). 
C. On the axial CT scan one week after treatment, the enhancing portion on the arterial and portal phases has almost decreased and
larger area of low attenuation is seen as drug infusion defect (arrows). 
D. Gross specimen of the extracted liver shows massive necrosis of the tumor (arrows). 
E. Serial axial scans of FDG PET. Before treatment (left), the tumor is hypermetabolic with a SUV of 3.42 (arrow). It decreased to 2.00
immediately after treatment (middle, arrow), and it decreased more to 1.95 a week after the treatment (right, arrow). 
F. Hematoxylin-eosin staining of the cut surface of the specimen (x 1) revealed near total necrosis with a small proportion of residual
viable tumor. The tumor necrosis rate was 99.00%.
E F
DBrPA administrations showed a marked decrease in the
number of viable tumor cells and there was also replace-
ment by degenerated cells and persistent cell debris that
involved both the peripheral and central regions of the
tumors. Viable tumor cells were also observed in all
specimens. The tumor necrosis rate ranged from 50.00%
to 99.90% (85.48% 15.87 [mean SD]). In addition,
varying degrees of inflammatory changes were observed
around the tumor. 
Correlation between SUV and FDG PET and the
Tumor Necrosis Rate
The SUVs measured before, immediately after and a
week after 3-BrPA administration did not show any statis-
tically significant correlation (Spearman r = 0.07, p = 0.83,
Spearman r = 0.41, p = 0.22, Spearman r =  0.14, p =
0.69, respectively). Likewise, the decrease rates of SUV
immediately and one week after treatment and the tumor
necrosis rate showed no significant correlation (Spearman r
=  0.29, p = 0.41, Spearman r = 0.49, p = 0.89, respec-
tively) (Fig. 3). 
DISCUSSION
Antitumor Effect of 3-BrPA
The antitumor effect of 3-BrPA has already been
demonstrated by in vitro and in vivo experiments. A study
by Ko et al. revealed that 3-BrPA abolished cell ATP
production by suppressing both glycolysis and oxidative
phosphorylation via the inhibition of hexokinase II, and 3-
BrPA facilitated cell death in in-vitro experiments using rat
AS-30D cells and rabbit VX2 carcinoma cells (16). As for
the mechanism of cell death, Gwak et al. have shown that
3-BrPA induced apoptosis of HCC cell lines through the
activation of the mitochondrial apoptotic signaling
cascades (23).
VX2 tumor, although it is of a non-hepatic origin,
exhibits glucose metabolic properties that are characteris-
tics of many rapidly growing hepatomas, of which the
biochemical hallmarks are a high glycolytic/high hexoki-
nase phenotype (13, 16). Geschwind et al. reported that
direct intraarterial delivery of 3-BrPA to rabbit VX2 liver
tumors selectively inhibited the viability of cells, without
any significant damage to the surrounding liver tissue (17).
In another recent study by Ko et al., the highly glycolytic
HCC line of AS-30D tumor, which was grown either
internally (in the abdominal cavity) or externally (in the
upper back) in rats, was nearly completely eradicated by
intraperitoneal or direct intratumoral injection of 3-BrPA
(21).
The present study using VX2 carcinoma also
demonstrated a marked antitumor effect by intraarterial
injection of 3-BrPA. However, complete necrosis of the
tumor was not achieved in any tumor by a single intraarte-
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Fig. 3. Scatterplots show correlation between SUV and the tumor necrosis rate (%) immediately (A) and one week (B) after treatment. No
significant correlation between these parameters was observed (Spearman r =  0.29, p = 0.41 in A, Spearman r = 0.49, p = 0.89 in B). 
AB
Fig. 2. Line graph shows the chronological SUV changes of the
VX2 liver tumors in each animal. Seven animals showed a
gradually decreased SUV, but the other three animals showed
rising tendency of FDG uptake at one week after treatment. * Tx
= treatment.rial injection of 3-BrPA. In addition, the result of our study
differed from that of Geschwind et al.’s study (17), in
which nearly 100% tumor necrosis was obtained with
delivery of 25 ml of 0.5 mM 3-BrPA; that study had
similar tumor volumes and a shorter follow up period
compared with those of our study, whereas the same
proportion of tumor necrosis was achieved only when
using ten times the dose of 3-BrPA in our study. This
discrepancy between the studies remains to be solved with
additional experiments. 
Evaluation of the Antitumor Effect of 3-BrPA with CT
and PET Imaging and the Pathologic Correlation
On this study, CT demonstrated limitations for evaluat-
ing the tumor response to intraarterial 3-BrPA administra-
tion. Comparison of the tumor volumes was not feasible
because the peritumoral morphologic changes on CT made
exact demarcation of the initial tumor difficult (Fig. 1).
Even though we measured the post-treatment tumor
volumes on each gross specimen and found that the tumor
volume decreased after treatment, measurement errors
caused by different modality could be unavoidable. The
changes of the enhancement pattern on CT reflected the
antitumor effect of 3-BrPA by showing a decrease or
disappearance of arterial enhancement of the tumors
(Table 1). However, considering those tumors that showed
no residual enhancing part on post-treatment CT also had
varying degrees of viable tumor on pathology, CT
enhancement is not a reliable finding to monitor tumor
response to 3-BrPA.  
FDG was proven to be a suitable tumor-seeking agent in
both experimental and human studies (24, 25). Since FDG
accumulates in tumor tissue with increased glucose
metabolism, it can provide a useful indication of tumor
viability (26, 27). Oya et al. in their study reported that
fluorine-18-FDG uptake by the VX2 liver tumors was 3.5
0.9 times higher than that by the normal liver tissue;
therefore, the tumor-nontumor contrast was good on PET
scans (26).
There are important issues in PET imaging for an antitu-
mor treatment of hypermetabolic liver tumors, that is,
whether it is possible to predict its therapeutic effect in the
early stage of the treatment and whether it can depict
small residual viable tumor after treatment. Recent studies
have demonstrated the value of FDG-PET for assessment
of glucose metabolism in liver tumors and also the effects
of treatment such as transcatheter arterial chemoemboliza-
tion. Nagata et al. studied FDG-PET in patients with
malignant liver tumor, and they reported that FDG-PET
was more useful than other imaging methods and tumor
markers as a functional imaging modality for monitoring.
tumors (28). Okazumi et al. reported that the calculated
rate constants of FDG in patients’ liver tumors reflected
the differentiation of HCC and this may be useful in
quantitatively assessing tumor viability after treatment
(29). Torizuka et al. compared FDG-PET and histological
examination of HCC 3 45 days after TAE, and they
suggested that those tumors with decreased or absent FDG
uptakes were highly necrotic, and the PET findings
reflected tumor viability more accurately than the extent
of intratumoral iodized oil retention on CT images (30).
Oya et al. reported that a marked decrease of FDG uptake
corresponded with a decreased number of tumor cells after
TAE and irradiation in VX2 liver tumor (31). In addition,
Ko et al. in their recent study that was mentioned above,
evaluated the antitumor effect of 3-BrPA with FDG-PET
imaging in four rats with AS-30D tumors in their abdomi-
nal cavity and upper back via intraperitoneal or direct
intratumoral administration (21). However, to the best of
our knowledge, evaluation of the antitumor effect of
intraarterial administration of 3-BrPA with FDG-PET
imaging has not yet been reported on.
In this study, the FDG uptakes of all tumors before the
treatment were significantly higher than those of the
nontumorous liver parenchyma, indicating that VX2 liver
tumor has a highly glycolytic activity, and this agreed with
the data from previous reports on FDG-PET in VX2 tumor
(24, 29).
SUV was significantly decreased immediately after 3-
BrPA administration in all animals except one (animal 4),
which implies that the therapeutic effect of intraarterial
administration of 3-BrPA can be evaluated and semiquan-
tified immediately after the procedure by means of FDG-
PET imaging. In the one animal that did not show a signifi-
cant immediate response to 3-BrPA administration (animal
4, SUV: 6.50 to 5.07), it was difficult to explain the
delayed response on the one week follow up study.
On the one week follow up study, seven animals showed
further decreases in FDG uptake, but the other three
animals (animals 1, 2 and 6) showed a slight increase in
FDG uptake compared with that of immediate post-
treatment. On microscopic examination of the specimens,
all of the treated animals had residual viable tumors,
including the seven animals with persistent decrease in
FDG uptake on the one-week follow up PET scans. These
results indicate that immediate suppression of glycolysis by
intraarterial administration of 3-BrPA does not necessarily
mean ultimate tumor death after treatment and a single
intraarterial injection of 3-BrPA induces only partial tumor
necrosis of the tumor with interval re-growth of the
residual viable tumor. Considering the incomplete tumor
response after treatment, the intraarterial delivery of 3-
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the entire tumor or it doesn’t sustain the tumorocidal dose
for enough time to induce complete tumor necrosis.
Another possible explanation for the increasing tendency
of SUV in three animals in this study is the FDG uptake by
peritumoral inflammatory cells. According to Spaepen et
al., FDG uptake, as measured by SUV, correlated with the
number of metabolically viable cells regardless of whether
they were tumoral or non-tumoral in nature (32), and FDG
uptake can also occur by the macrophages within a tumor
mass, and especially after chemotherapy. Our histologic
slide review revealed peritumoral inflammatory cell
infiltrations in all animals. However, the degree of inflam-
mation was not apparently higher in those three animals
compared with the others, and it was not possible to differ-
entiate the FDG uptake by the inflammatory cells from the
viable tumor cells with the resolutions of the images in our
study. 
Against our expectation, we failed to demonstrate
quantitative correlation between SUV or a decreased rate
of SUV and the tumor necrosis rate after treatment. This
may be due to inherent limitation of a FDG-PET scan to
detect a small viable fraction of small tumors, or the SUV
uptake by peritumoral inflammatory cells can be one of
the reasons. In this study, the VX2 tumors showed a high
tumor necrosis rate (mean: 85.48%) after intraarterial
injection of 3-BrPA. According to the comparative study
by Torizuka et al. of FDG-PET and the histological finding
of HCC after TAE, an SUV ratio more than 0.6 suggested
residual viable tumor, whereas an SUV ratio of 0.6 or less
indicated more than 90% tumor necrosis (30). One thing
to be noticed is that they covered tumors with a wide
range of necrosis rates, from less than 25% to near 100%;
when only the tumors with a higher necrosis rate (> 80%)
were taken into consideration, quantitative correlation
between FDG uptake and the tumor necrosis rate was not
achieved either. 
Limitations
There are potential limitations of this study that must be
mentioned. First, the follow up period after 3-BrPA
administration was too short since all the experimental
animals were sacrificed together a week after the
treatment for the histological correlation. Therefore, the
FDG uptake after treatment was not correlated with other
parameters when evaluating the therapeutic response, such
as the tumor volume change and survival of the animals.
Especially in case of the animals with an increasing
tendency of FDG uptake a week after treatment, a longer
period of follow up seems to be necessary for determining
how the FDG uptake changes thereafter. Second, even
though we used dual-phase liver CT for localizing tumors
on PET scan, there were difficulties in accurately measur-
ing the tumor areas and some errors happened when
calculating the FDG uptake in tumors and the SUV.
Moreover, since we used a conventional PET scanner in
this animal study, errors due to partial volume artifacts
were inevitable. A PET-CT scanner and an animal PET
scanner with higher resolution may help reduce such
errors.  
CONCLUSION
Intraarterial administration of 3-BrPA in a VX2 liver
tumor model showed an antitumor effect via suppression
of glycolysis, and FDG-PET can be a useful modality for
the early evaluation of this treatment, even though FDG-
PET cannot exactly reflect the tumor necrosis rate. 
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